Mogrify
PrivateLast Round
Series A
Extension
Oct 2, 2023
Total Funding Raised
$77.8M
Company Overview
Mogrify operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Series A Extension round in October 2023.
Mogrify is a biotechnology company that develops proprietary platform technologies for direct cellular reprogramming to create a novel class of in vivo reprogramming therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mogrify Comparables
Compare Mogrify with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| iReprogram, Inc. | 89% | |
| bit.bio | 78% | |
| GC Therapeutics | 77% |
For institutional investors. Book with your work email.
Mogrify Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 2, 2023 | ||||
| Series A Extension | May 4, 2021 | ||||
| Grant | Jan 28, 2020 | ||||
| Series A | Oct 14, 2019 | ||||
| Seed | Feb 20, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Mogrify Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SBRI Healthcare | Grant |
| Innovate UK | Seed |
| Astellas Venture Management | Series A Extension, Series A |
| Ahren Innovation Capital | Series A Extension, Seed, Series A |
| Parkwalk Advisors | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 83% MoM.
- Jan 28, 2020
$1.1M grant received from SBRI Healthcare
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 11, 2026
Mogrify Limited plans to present preclinical proof-of-concept data on its investigational retinal regeneration therapy at the FLORetina-ICOOR 2026 Congress on Dec 3rd-6th '26.
For institutional investors. Book with your work email.
Mogrify Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mogrify's valuation, stock price, and market status.
Is Mogrify a public or private company?
Mogrify is a private company.
What is the current stock price of Mogrify?
Mogrify is a private company, so its shares have no public market price. Caplight tracks Mogrify's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mogrify worth (valuation)?
Valuation information for Mogrify is not publicly available.
Can I buy Mogrify stock?
Mogrify shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mogrify's last funding round?
Mogrify's most recent funding round was Series A Extension on October 2, 2023.
Who are the main investors in Mogrify?
Key investors in Mogrify include Astellas Venture Management, Ahren Innovation Capital, Parkwalk Advisors.
Will Mogrify IPO soon?
No public IPO plans have been announced for Mogrify.
How can I track Mogrify secondary market activity?
Caplight tracks bids, offers, and trades in Mogrify's shares on secondary markets.